Calif. bills
This article was originally published in The Rose Sheet
Executive Summary
California Safe Cosmetics Act of 2005 (SB 484) clears state Senate in a 23-15 floor vote May 31. Bill, which would authorize the Department of Health Services to investigate cosmetics containing chemicals identified by the state as causing cancer or reproductive toxicity and require manufacturers of such products to submit relevant health effects data to DHS, will next be taken up by the state Assembly. SB 484 was introduced by Sen. Carol Migden (D-3rd) (1"The Rose Sheet" April 4, 2005, p. 3). In addition, The Healthy California Biomonitoring Program (SB 600), sponsored by Sen. Deborah Ortiz (D-6th), is approved on the Senate floor 21-14. Legislation would establish statewide biomonitoring system and require DHS to appoint an advisory panel, which would assist in carrying out the program and identifying priorities for biomonitoring. Program may affect consumer products like beauty and personal care items...
You may also be interested in...
SB 484
California Safe Cosmetics Act is slated to be addressed by Assembly Committee on Health June 28. Sponsored by Sen. Carol Migden (D-3rd), legislation seeks to authorize state Department of Health Services to investigate cosmetics containing chemicals identified as causing cancer or reproductive toxicity and require manufacturers of such products to submit relevant health effects data to DHS. SB 484 cleared the Senate May 31 (1"The Rose Sheet" June 6, 2005, In Brief)...
California Dreaming? Dems Re-Introduce Legislation To Regulate Cosmetics
Manufacturers of cosmetics subject to FDA regulation and sold in California would be required to report to the Department of Health Services any ingredient containing a chemical known to the state as causing cancer or reproductive toxicity under legislation pending in the state senate
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.